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Introduction: Preeclampsia (PE) is a multifactorial disease characterized by high blood pressure and
proteinuria after the 20th week of pregnancy. PE is associated with ﬁbrin deposition in placental
microcirculation and intrauterine fetal growth retardation. We evaluated FVIII activity, VWF and ADAMTS13
plasma levels, according to O and “non O” blood groups, in women with severe PE (sPE).
Methods: This case-control study included 140 women; 55 pregnant with sPE, 35 normotensive pregnant and
50 non-pregnant women. VWF and ADAMTS13 antigen levels were assessed by ELISA (American
Diagnostica). FVIII activity was measured by automated coagulometric method (Dade Behring) and ABO
blood groups phenotyping was performed by indirect technique.
Results: FVIII activity and VWF levels were signiﬁcantly higher comparing either sPE to normotensive
pregnant (P=0.01; P=0.05) and to non-pregnant women (P=0.00 in both cases) or normotensive pregnant
and non-pregnant women (P=0.00 in both cases). A signiﬁcant decrease in ADAMTS13 levels was observed
comparing either sPE to normotensive pregnant (P=0.02) and non-pregnant women (P=0.00) or
normotensive pregnant and non-pregnant women (P=0.00). FVIII activity and VWF levels were associated
to O and “non O” blood groups only in non-pregnant women.
Conclusions: The increase of FVIII activity and VWF levels and the decrease of ADAMTS13 in sPE are not
associated to O and “non O” blood groups. These alterations in hemostatic markers in sPE largely surpass those
physiologically determined by ABO blood groups inﬂuence and may have masked the effect of O and “non O”
groups in this disease. A concomitant analysis of VWF levels and ADAMTS13 activity and antigenic levels will
be important to clarify the imbalance between these parameters found in sPE in the present study.
© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Preeclampsia (PE) is a multifactorial disease characterized by the
presence of high blood pressure and proteinuria after the 20thweek of
pregnancy. Clinically is relevant to subdivide this disease in two
categories, mild PE and severe PE (sPE), according the severity of the
symptoms [1]. This disease can progress to eclampsia (characterized
by seizures as a sign of affection of the cerebral vessels), syndrome
HELLP (hemolysis, elevated liver enzyme, low platelets) or dissemi-
nated intravascular coagulation [2]. The etiology of the PE is unknown
and it is associatedwith ﬁbrin deposition in placentalmicrocirculation
and intrauterine fetal growth retardation [3].
The VWF is an important component of the haemostatic system and a
hypercoagulability state biomarker. TheVWF is amultimeric glycoprotein
synthesized in endothelial cells and megakaryocytes. VWF dimers areoxicological Analysis, Faculty of
31270–901, Belo Horizonte/MG,
85.
@gmail.com (L.M. Dusse).
evier OA license.secreted into the plasma and the subendothelium, whereas ultra large
VWF (ULVWF) are storedwithin theWeibel–Palade bodies of endothelial
cells and their release to plasma is limited to sites of endothelial damage
[4,5]. Thus, the presence of endothelial injury leads to a signiﬁcant
increase of VWF levels in plasma [6,7]. VWF directly contributes to
thrombus formation by mediating platelet adhesion to subendothelial
collagen and, indirectly, by carrying FVIII and by preventing its plasmatic
clearance [8]. This may explain the association of elevated levels of FVIII
and VWF with thromboembolism and atherosclerosis [9,10].
Furlan [11] et al. andTsai et al. [12] isolated aprotease thatwas able to
cleave the peptide bond between tyrosine at position 1605 and
methionine at position 1606, in the central A2 domain of VWF. In a
retrospective cohort study, patients clinically diagnosedwith thrombotic
thrombocytopenic purpura displayed either qualitative, quantitative
deﬁciency or auto-antibodies against this protease. Zheng et al. [13]
identiﬁed this protease as a new member of the ADAMTS family of
metalloproteases and named it ADAMTS13. ADAMTS13 normally
circulates in plasma and has a mass of approximately 150 kDa [14,15].
Under physiological conditions, ADAMTS13 promptly cleaves and
removes from circulation ULVWF, which are released from endothelial
Table 1
Characteristics of participants.
Severe PE
(N=55)
Normotensive
pregnant
(N=35)
Non pregnant
women
(N=50)
P value
GA (weeks) 33 (31–36) 33 (32–36) – NS
GWG (Kg) 13 (9–16) 11 (7–15) – 0.05
Nº of gestations 0 (0–1) 0 (0–1) – NS
Age (y) 26 (21–30) 24 (18–31) 26 (23–30) NS
BMI (kg/m2) 23 (21–29) 23 (21–25) 22 (20–25) NS
SBP (mmHg) 167 (130–220) 110 (100–130) 120 (80–130) 0.00
DBP (mmHg) 100 (80–150) 70 (60–90) 80 (60–90) 0.00
GA: gestational age; GWG: gestational weight gain; Nº: number; BMI: body mass index;
SBP: systolic blood pressure; DBP: diastolic blood pressure-Values are presented as
median (25th–75th centiles).
(–): does not apply.
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ADAMTS13 deﬁciency and/or the presence of antibodies against this
enzymemay increaseULVWFplasma levels, thus favoring theoccurrence
of thrombosis in small vessels [8,18].
It is known that individuals from blood group O have signiﬁcantly
lower plasma levels of VWF and FVIII than those from blood group “non
O” (A, B or AB) [19–23]. Therefore, “non O” subjects present increased
risk for venous thrombosis [20–25]. Over many years, studies have
investigated the association between ABO blood groups and PE [26–32],
but no consensus exists related to this association.
An increase of FVIII plasma levels have already been found in women
with PE [33]. On the other hand, low plasma ADAMTS13 activity was
reported in patients with HELLP syndrome [34,35]. Despite the
knowledgeonhaemostasis inPE, scantdatahavebeen reported regarding
the correlation between coagulation markers and O and “non O” blood
groups in preeclamptic women. Therefore, the aim of this study was to
evaluate the activity of FVIII, VWF and ADAMTS13 plasma levels,
according to O and “non O” blood groups in women with sPE.
2. Material and methods
2.1. Ethical aspects
The Ethics Committee of Federal University of Minas Gerais
approved the study and informed consent was obtained from all
participants. The research protocol did not interfere with any medical
recommendations or prescriptions.
2.2. Study design
The present case-control study included 140 women; 55 pregnant
with sPE, 35 normotensive pregnant and 50 non-pregnant women.
Severe preeclamptic women were selected from Odete Valadares
Maternity-Belo Horizonte/Brazil and Regional Public Hospital of
Betim/Brazil. Normotensive pregnant and non-pregnant women were
selected from Healthy Center Guanabara, Betim/Brazil.
2.3. Inclusion criteria
Severe PE was deﬁned by systolic blood pressure ≥160 mmHg or
diastolic blood pressure ≥110 mmHg; on ≥2 consecutive occasions
≥4 h apart; and proteinuria N2 gL−1 or at least 2+ protein by
dipstick. The normal pregnant women had systolic/diastolic blood
pressure below 120/80 mmHg and no history of hypertension or
proteinuria. All pregnant women were gestational age ≥29 weeks
[33]. Non-pregnant women had no clinical and laboratory alterations.
2.4. Exclusion criteria
Exclusion criteria common for the 3 groups were chronic hyperten-
sion, coagulation disturbance or haemostatic abnormalities, cancer,
diabetes, cardiovascular, autoimmune, renal and hepatic diseases,
anticoagulant or corticosteroids therapy.
2.5. Blood sampling
Blood samples were drawn in sodium citrate (0.129 mol/l) in 9:1
volume ratio. Citrated blood samples were centrifuged at 2,500 Xg for
20 min at 4 °C to obtain plasma. Samples were aliquoted and stored at
−70 °C until analysis.
2.6. Assays
Speciﬁc commercially available enzyme-linked immunosorbent
assay (ELISA) kits (Imubind®; American Diagnostica Inc., Stamford,
CT) were used, according to theManufacturer's instructions tomeasureVWF and ADAMTS13 antigen levels. FVIII activity was measured by
automated coagulometric method (BFT* II Analyzer – Dade Behring®,
Alemanha). ABO blood groups phenotyping was performed by indirect
technique.
3. Statistical analysis
Statistical analyses were performed using SPSS software (ver 13.0,
SPSS). Shapiro-Wilk tests were used to test if variables were normally
distributed. Data not normally distributed were compared by the
Kruskal–Wallis H test. The comparison of results between two groups
was made using the Mann–Whitney U test. Values are presented as
median (25th–75th centiles). The comparison of categorical variable (O
and “non O” blood groups) was performed by χ2. Multivariate logistic
regression analysis was performed to assess whether higher FVIII
activity, VWF levels and lower ADAMTS13 levels are independent risk
factors for PE. FVIII values were split in 2 categories according the range
provided by Dade Behring (N150% vs. b150%). Similarly, ADAMTS13
values were split in 2 categories according the range provided by
American Diagnostica (b630 ng/mL vs. N630 ng/mL). For VWF, since
there is not a range provided by American Diagnostica the values were
split according to the 75% of the interquartile interval detected for the
group of non-pregnant women, higher than 1859 mU/ml vs. less than
1859 mU/ml. sPE was the dependent variable. Values of P≤0.05 were
accepted as statistically signiﬁcant.
4. Results
Table 1 summarizes the clinical characteristics of the 140 women
enrolled in this study.No statistical differenceswere found for gestational
age and gestations numbers, comparing severe preeclamptic women
with normotensive pregnant, while the gestational weight gain was
higher in sPE (P=0.05). No differences were found for age and body
mass index among the three groups. However, systolic and diastolic
blood pressure were signiﬁcantly higher inwomenwith sPE (P=0.00 in
both cases).
Hemostatic data are summarized in Table 2. FVIII activity and VWF
levels were signiﬁcantly higher in sPE group, as compared to normoten-
sive pregnant women (P=0.01 and P=0.05, respectively) or to non-
pregnant women, and (P=0.00, in both cases). An increased activity of
FVIII and VWF plasma levels were found comparing normotensive
pregnant and non-pregnant women (P=0.00, in both cases). A
signiﬁcant decrease in ADAMTS13 levels was observed in sPE group, as
compared tonormotensivepregnantgroup(P=0.02)or tonon-pregnant
women (P=0.00). Similarly a decrease inADAMTS13 levelswas found in
normotensive pregnant comparing to non-pregnant women (P=0.00).
Thewomen from the 3 groupswere placed into 2 categories; O and
"non O" blood groups, to compare FVIII activity and VWF and
ADAMTS13 levels. The frequency of O and “non O” blood groups in sPE
Table 2
Haemostatic parameters.
Parameters Severe PE
(N=55)
Normotensive
pregnant
(N=35)
Non pregnant
women
(N=50)
P value
F VIII (%
activity)
232 (154–300) 152 (117–200) 81 (62–106) 0.00
VWF
(mU/ml)
2270 (1779–
4353)
1877 (1489–
2769)
1303 (1018–
1859)
0.00
ADAMTS-13
(ng/ml)
567 (486–688) 635 (565–764) 783 (689–998) 0.00
Values are presented as median (25th–75th centiles). Kruskal–Wallis test.
F VIII: factor VIII; VWF: von Willebrand factor; ADAMTS13: a disintegrin and
metalloprotease with eight thrombospondin-1-like domains-13.
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and 57% in normotensive pregnant, respectively, P=0.25).
Table 3 shows the comparison of haemostatic parameters in the 3
groups, according toOand “nonO”blood groups. Therewas a signiﬁcant
increase in FVIII activity and VWF levels in non-pregnant women from
blood groups “non O”, comparing to those from group O (P=0.01 and
P=0.04, respectively). On the other hand, no difference was found for
ADAMTS13. No differences were found comparing FVIII activity, VWF
and ADAMTS13 levels in sPE and normotensive pregnant groups,
according to O and “non O” blood groups.
Univariate analysis was performed including the variables age,
multiple pregnancy, number of pregnancy, miscarriage, gestational
weight gain, O and “non O” blood groups, FVIII activity, VWF and
ADAMTS13 levels. Those variables whose Pb0.20 were selected to the
multivariate logistic regression. In the ﬁnal model, only FVIII, VWF and
ADAMTS13 showed independently associated to sPE (P=0.01, P=0.01
and P=0.00, respectively). Higher FVIII activity (N150%) and VWF
(N1859 mU/ml) were associated to an increased probability of
developing sPE (OR 4.02, 95% CI [1.53–10.55], P=0.01 and OR 3.88
95% CI [1.45–10.39], P=0.0, respectively). On the other hand, lower
ADAMTS13 levels (b630 ng/mL) were associated with an 8.77 fold
chance of sPE occurrence (OR 8.77, 95% CI [2.40–32.06], P=0.00).
5. Discussion
This study showed an increase in FVIII activity and VWF levels in
sPE women, as compared to normotensive and non-pregnant women.Table 3
Haemostatic parameters in preeclamptic, normotensive and non-pregnant women,
according to blood group O and “non O”.
Parameters/groups Blood groups P
O Non O
F VIII (% activity) Severe PE 187 (117–300) 254 (180–300) NS
(n=17) (n=38)
Normotensive 144 (128–199) 159 (117–250) NS
(n=15) (n=20)
Non pregnant 72 (60–106) 95 (84–114) 0.01
(n=27) (n=23)
VWF (mU/ml) Severe PE 1972 (1644–2766) 2350 (1890–4885) NS
(n=17) (n=38)
Normotensive 1849 (1351–2530) 1998 (1509–3031) NS
(n=15) (n=20)
Non pregnant 1323 (899–1858) 1936 (1145–2606 0.04
(n=27) (n=23)
ADAMTS-13
(ng/ml)
Severe PE 567 (505–665) 578 (486–688) NS
(n=17) (n=38)
Normotensive 627 (594–683) 659 (561–769) NS
(n=15) (n=20)
Non pregnant 751 (632–970) 725 (604–962) NS
(n=27) (n=23)
Data are presented as median (25th–75th centiles). Mann–Whitney test.
F VIII: factor VIII; vWF: von Willebrand factor; ADAMTS13: a disintegrin and
metalloprotease with 8 thrombospondin-1-like domains-13.Besides, it was observed an increase in FVIII activity and VWF levels in
normotensive pregnant women comparing to non-pregnant women,
conﬁrming the physiological hypercoagulable state of pregnancy
(Table 2). Similarly to our results, Thornton et al. [33] veriﬁed an
increase of the FVIII antigen:FVIII activity in sPE women, compared to
normotensive pregnant. De Boer et al. [36] and España et al. [37]
reported an impairment of natural anticoagulation through protein C
in PE women which may justify the increase of FVIII in this disease,
since protein C acts by inactivating factors V and VIII.
The higher FVIII activity in PE has been also associated to the
inﬂammatory process present in this disease [38,39], since FVIII is also
an acute phase protein [38]. In addition, it is known that cytokines
such as tumor necrosis factor α (TNF-α), interleukin-8 (IL-8) and
interleukin-6 (IL-6) promote ULVWF release from endothelial cells to
plasma [5]. Therefore, the inﬂammatory response and endothelial
injury observed in PE [40] may as well explain the increase of VWF in
this disease.
Reduced ADAMTS13 plasma levels were found in PE women,
comparing to normotensive pregnant women and non-pregnant
women (Table 2). Since this enzyme is required for cleavage and
clearance from circulation of ULVWF, its reduced levels may explain
the higher VWF in sPE patients. It is worth mentioning that the
antibody capture ELISA test used to detect VWF recognizes mainly
ULVWF. A probable explanation for ADAMTS13 quantitative deﬁciency
could be its loss through urine since severe preeclamptic women
presented a signiﬁcant proteinuria. Although in distinct disease
pathologies, Mannea et al. [41] reported low levels of plasmatic
ADAMTS13 in patients with nephrotic syndrome and post-infectious
gromerulonephritis presenting proteinuria due to unselective leak of
plasma proteins into urine. Alternatively, in the presence of higher
VWF levels the turnover of ADAMTS13 may be increased. There are
evidences that ADAMTS13 proteolysis is performed by plasmatic
proteases such as thrombin [42] or by proteases released by
granulocytes [43]. Since sPE is associated to hypercoagulability and,
consequently, increased thrombin levels, it is plausible to hypothesize
that the increased thrombin levels may act by enhancing ADAMTS13
turnover. However, additional studies are required to investigate if this
mechanism is also active in sPE.
Few studies have assessed VWF and ADAMTS13 in preeclamptic
women. In agreement to our results, Lattuada et al.[35] have also
reported signiﬁcantly lower ADAMTS13 activity in HELLP syndrome
women comparing to healthy pregnant and non-pregnant women.
These authors observed that reduced ADAMTS13 levels were not due
to the presence of inactivating auto-antibodies and that ADAMTS13
levels returned to normal after labor. Similar results were found by
Hulstein et al. [34] and Stepanian et al. [44] who observed increased
VWF levels and decreased ADAMTS13 activity in HELLP syndrome or
PE comparing to normotensive pregnant, respectively. However,
Molvarec et al. [45] and Zhang et al. [46] found increased VWF
antigen levels but normal ADAMTS13 activity in preeclamptic women
comparing to normotensive pregnant.
Possible explanations for these discrepant ﬁndings in ADAMTS13
assessment in PE are the number of patients enrolled in each study,
the inclusion and exclusion criteria of the cases and controls and the
gestational age of pregnant in each study. Furthermore, in some
studies ADAMTS13 antigen levels weremeasured by ELISAwhereas in
others activity was evaluated, which may have also contributed to
these different ﬁndings. Therefore, a concomitant analysis of
ADAMTS13 activity and antigenic levels will be important to clarify
the imbalance between ADAMTS13 and VWF levels found in
preeclamptic women in the present study.
The increased levels of ULVWFmay be directly associated with the
diffuse occlusion of placental and renal arterioles frequently found in
PE [47]. It should be highlighted that platelets do not adhere to small
forms of VWF that circulate after cleavage of ULVWF by ADAMTS13.
However, platelets bind to ULVWF, resulting in platelet aggregates,
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the placenta microcirculation [4,5,48].
It is known that FVIII and VWF levels are signiﬁcantly higher in
subjects from “non O” (A, B and AB) blood groups, comparing to those
from O and this has been associated with development of venous
thrombosis. Indeed, for non-pregnant women FVIII activity and VWF
levels were signiﬁcantly increased in “non O” blood groups women
comparing to those with O, which is in agreement to literature data. No
association was found between O and “non O” blood groups and
ADAMTS13 levels. Contrary to our results, Mannucci et al. [49] found
decreased ADAMTS13 levels in “non O” subjects.
Based on these ﬁndings, one would expect to ﬁnd an increased
frequency of “non O” blood groups among severe preeclamptic women,
since they present higher levels of VWF and FVIII. However, no
signiﬁcant differences were observed for frequencies of O and “non O”
groups between severe preeclamptic and normotensive pregnant.
Previous studies [31,32] have reported that the AB blood group is
associatedwith PE. Since the frequency of AB in the Brazilian population
is approximately 4%, the small sample size of the present study has not
enough power to detect this association.
On the other hand, the lack of association between O and “non O”
blood groups and FVIII activity and VWF levels in sPE women could be
explained by the signiﬁcant decrease in ADAMTS13 levels observed in
these patients. It has been estimated that ADAMTS13 levels are 10%
lower in “non O” blood groups' carriers, which explain at least in part
the differences in VWF levels determined by ABO blood groups [46]. In
the present study, the ADAMTS13 levels average values in sPE women
were decreased in 11% and 28%, as compared to normotensive
pregnant and non-pregnant women, respectively. We hypothesized
that the reduction in ADAMTS13 levels in sPE women largely surpass
those physiologically determined by ABO blood groups inﬂuence and
may have masked the effect of O and “non O” blood groups in this
condition. The ﬁnding of association between O and “non O” groups
and FVIII activity and VWF levels observed in this study for non-
pregnant women supports this assumption. These data suggest that
the hypercoagulability state in pregnancy and sPE is indeed a complex
event, with several factors acting together. A limitation of this study is
the low sample size, which has an inappropriate statistical power to
investigate the effect of O and “non O” blood groups in hemostatic
parameters.
Despite intensive research, PE remains one of the leading causes of
maternal death worldwide. The only deﬁnitive treatment is to deliver
the baby and placenta, often prematurely, in the interest of the baby, the
mother, or both. Therefore, it would be very desirable to clarify the
haemostatic alterations in severe preeclamptic women and to establish
the real role of laboratorial biomarkers to monitor these pregnant. The
present data suggest thatmonitoring FVIII, VWFandADAMTS13may be
relevant procedure for this purpose.Acknowledgements
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